What Is Liraglutide? The First Acylated GLP-1 Analogue: Structure, Mechanism and Research

Liraglutide is a palmitoylated GLP-1 receptor agonist of 31 residues — the molecule that pioneered the lipidation strategy now used throughout the incretin class. Relative to the natural hormone, one residue is swapped and a sixteen-carbon palmitoyl chain is attached (C16), which stretches its time in the circulation from minutes to hours. That window is practical for experiments, yet brief enough that liraglutide answers different questions from the analogues lasting several days that followed it. Our research-grade liraglutide ships freeze-dried in sealed vials and is meant for laboratory work only.

Human clinical data concern the licensed medicines that contain this molecule. They describe a regulated pharmaceutical, not the reference material sold on this page.

Liraglutide defined

What makes native GLP-1 impractical as a tool is its one-to-two-minute plasma half-life, the result of DPP-4 cleavage and rapid clearance by the kidney. Liraglutide was the first-generation fix. It keeps the GLP-1(7-37) sequence nearly intact, changing only Lys34 to arginine, and hangs a C16 palmitic acid on Lys26 through a glutamic acid linker. The fatty acid does two jobs: it binds albumin reversibly, shielding the peptide from elimination, and it makes the molecules associate into heptamers in solution and at the injection depot, slowing release still further.

That near-identity with the natural hormone is what keeps liraglutide relevant. If you want a GLP-1 receptor agonist whose sequence stays as close to endogenous GLP-1 as stability allows, liraglutide suits better than semaglutide, which brings in a non-natural Aib residue and a longer fatty diacid.

Design and structure

• Sequence. GLP-1(7-37), 31 residues, with one substitution: Lys34 to Arg.
• Lipidation. A C16 palmitic acid attached to Lys26 via a γ-Glu linker — a shorter, single-acid lipid than the C18 and C20 diacids used in later analogues.
• No Aib at position 8. Liraglutide retains the natural alanine at position 8, so DPP-4 can still cut it. It lasts longer because of albumin binding and self-association, not because it resists the protease — the single most important structural point about this molecule.
• Identifiers. CAS 204656-20-2; formula C172H265N43O51; molecular weight 3751.20 Da, making it the lightest lipidated GLP-1 analogue we stock.

Mechanism of action

At the receptor, it behaves like any member of the class. Liraglutide binds the GLP-1 receptor, a class B GPCR, stabilises its active conformation and stimulates Gs-coupled cAMP production, with signalling onward through PKA and Epac2. In isolated islets this amplifies insulin secretion — but only when glucose is elevated. Rodent studies link reduced feeding and slower gastric emptying to receptors in the hindbrain (area postrema, nucleus of the solitary tract), the hypothalamic arcuate nucleus and on vagal sensory fibres.

Where liraglutide parts company with its successors is exposure, not receptor biology. Hour-scale duration gives peaks and troughs; a multi-day analogue comes close to constant exposure. Even at the same receptor these are two different pharmacological experiments, and several published results on desensitisation and tachyphylaxis in GLP-1 research depend on which pattern was used. If your question is about intermittent versus sustained receptor occupancy, that difference is what you are testing — not a confounder.

Research applications

• Cell and receptor assays. Measurements of cAMP, binding, arrestin recruitment and internalisation in cells carrying the human GLP-1 receptor. Liraglutide is a routine reference agonist in this work, and most newer compounds are characterised relative to it.
• Biophysical studies. Work on self-association and heptamer formation, albumin binding and formulation stability — an unusually rich strand for liraglutide, because its self-association governs its kinetics.
• Animal studies. Feeding, gastric transit, islet structure and beta-cell mass, maps of neuronal activation, and models of fatty liver and neuroinflammation.
• Trials of the licensed medicines. Large randomised studies in weight management and in type 2 diabetes, and a cardiovascular outcomes trial that has been published. All of these tested prescription drugs under medical supervision and tell you nothing about research-grade powder.

For the broader picture, see the GLP-1 and incretin pathway hub.

Its history also matters when reading the literature. Being the first lipidated GLP-1 analogue studied in depth, liraglutide was the workhorse for establishing core GLP-1 receptor pharmacology: how fast the receptor internalises and recycles, and how cAMP output relates to insulin release in isolated islets. Later compounds are usually benchmarked against liraglutide rather than against native GLP-1, so using the same reference agonist when you repeat or extend a published comparison removes a whole class of between-study inconsistencies.

Available formats and vial sizes

Vial sizes and prices are listed on the liraglutide product page, part of the GLP-1 and incretin peptides collection.

Reconstitution and storage at the bench

Working out the concentration is routine. Put 2 mL of bacteriostatic water into a 5 mg vial for 2.5 mg/mL (2,500 mcg/mL); every 0.1 mL then carries 250 mcg. What is unusual about liraglutide is how its self-association responds to pH: solubility is best on the slightly alkaline side and worst close to the pI, where the peptide may precipitate. A cloudy solution usually signals a buffer-pH problem rather than breakdown — and vigorous shaking to redissolve it causes more harm than simply adjusting the pH.

Store unopened freeze-dried vials at −20 °C, dry and away from light. Keep reconstituted solution at 2–8 °C and use it within the study. Aliquot when you reconstitute instead of repeatedly freezing and thawing a common stock. See our reconstitution guide and the note on pH and solubility.

Self-association has another practical consequence. Because heptamer formation depends on concentration, a strong stock and its dilute working solution hold different populations of monomer and oligomer: at assay strength liraglutide is mostly monomeric, whereas in a concentrated stock much of it is associated. That becomes relevant when you prepare a stock far above working strength and store it, since the association state during storage is not what exists in the assay well, and re-equilibration is not instantaneous. Leaving diluted solutions to settle before measurement, rather than diluting seconds before the read, takes out a genuine source of noise.

Purity and reading the certificate of analysis

Expect the certificate to include an HPLC trace with main-peak area percentage, a mass-spectrometric identity check against the calculated 3751.20 Da, net peptide content, lot number and analysis date. With a lipidated peptide produced this way, two kinds of impurity are worth attention. One is peptide that never received its palmitate: it acts for a shorter time with different kinetics, but may barely register in the headline purity figure. The other is deletion or des-amino sequences from incomplete coupling steps. A trace with resolved shoulders tells you more than any single percentage. See how to read a COA, and confirm the lot matches your vial.

Finally, a shorter half-life is not necessarily a weakness in the lab. Because liraglutide clears within hours, you can wash it out and return to baseline inside a single experiment — impossible with a multi-day analogue unless you add a week to the study. For crossover designs, repeated-measures protocols and questions about how receptor responsiveness recovers after exposure, that is a positive reason to choose liraglutide rather than reaching automatically for the most potent long-acting compound.

Regulatory position

As a medicine, liraglutide is an authorised prescription product in the EU, the United States and many other countries, and since the originator's patents expired, generic versions have appeared in several markets. Research-grade liraglutide is in an entirely separate category: a chemical reference material for laboratory research, not for use in humans. Patent status changes nothing about that.

Related compounds and comparisons

Its obvious comparator is the longer-acting successor on the same backbone, covered in liraglutide vs semaglutide (the semaglutide product page lists that option). For agonists acting at several receptors, see retatrutide; for the older exendin-derived agonist, see exenatide.

Matching catalogue section: GLP-1 & Incretin Peptides